Hepatitis B reactivation during glioblastoma treatment with temozolomide: A cautionary note

Neurology

Volumn 68, Issue 12, 2007, Pages 955-956

  Chheda, M G ^a,b   Drappatz, J ^a,b   Greenberger, N J ^a   Kesari, S ^a,b   Weiss, S E ^b   Gigas, D C ^b   Doherty, L M ^b   Wen, P Y ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ATOVAQUONE; DEXAMETHASONE; ERLOTINIB; ETIRACETAM; LAMIVUDINE; LOMUSTINE; TEMOZOLOMIDE; TOLTERODINE;

ADULT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; CRANIOTOMY; DRUG DOSE REDUCTION; GLIOBLASTOMA; HEPATITIS B; HUMAN; LABORATORY TEST; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA, VIRAL; GLIOBLASTOMA; HEPATITIS B; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; PATIENT SELECTION; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SPINAL NEOPLASMS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION;

EID: 34147178313     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000259430.48835.b5     Document Type: Article

References (7)

1. Sun Z, Ming L, Zhu X, Lu J. Prevention and control of hepatitis B in China. J Med Virol 2002;67:447-450.
2. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-1089.
3. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-1311.
4. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861.
5. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
6. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;:987-996.